ESG

EyeYon Medical's synthetic corneal implant, EndoArt, just got FDA approval for U.S. trials, offering a fix for the global donor tissue shortage.

Newron launches a pivotal US trial for its novel schizophrenia drug, evenamide, aiming to help millions who don't respond to current treatments.

New data reveals Syndax's Revuforj is a game-changer for leukemia, sparking a battle for market dominance in targeted cancer therapy.

A breakthrough drug for a rare brain cancer sweeps prestigious international awards, offering patients a new, targeted therapy to delay aggressive treatments.

A breakthrough eco-friendly antioxidant, SA6000, could slash the environmental impact of tires. But can this molecular innovation scale for global impact?

A new $4.2 billion coastal city in Muscat aims to merge luxury living with a digital economy. Can Oman's 'MAD' project redefine real estate and its future?

AsymBio's massive Shanghai facility isn't just about capacity; it's a key move in the high-stakes world of advanced biologic drug production.

New 52-week data shows Protagonist and Takeda's drug slashes phlebotomy needs, signaling a major shift in quality of life for polycythemia vera patients.

A medical breakthrough dismantles a core barrier in cancer treatment, making stem cell transplants a reality for nearly everyone, regardless of ancestry.

A government crackdown on clergy and a top businessman raises serious questions about Armenia's judicial independence, spooking investors and allies alike.

Boston-based 1910 Genetics unveils an AI model that bypasses decades-old barriers, opening a vast new frontier for treating Alzheimer's and Parkinson's.

A utility is slashing its carbon footprint by 99.9% not with solar or wind, but with an invisible innovation that fixes the grid from the inside out.

Chile's state oil firm is using strong profits to buy back $150M in debt. Is this just smart accounting, or a move to fund its green hydrogen ambitions?

Massey Ferguson's award to the World's Oldest Rodeo is more than a gift; it's a strategic look at how heritage brands are powering community impact.

The G7 has unveiled a new blueprint for the future of work, balancing AI innovation with a major push for inclusive employment. What does it mean?

New data on RAP-219 reveals more than just seizure control; it shows a strategic play to redefine treatment and capture the neurology market.

KB Home's new Port Orchard community isn't just about houses; it's a new model for building that merges personalization, deep energy savings, and market strategy.

Lexicon's sotagliflozin may revolutionize HFpEF treatment by targeting adipose tissue, a move that could differentiate it in a crowded market.

A Japanese genomics leader is using AI and a massive local database to offer personalized cancer risk predictions, a move that could redefine preventative care.

A bioengineering firm is tapping deceased donors for bone marrow, promising to end shortages and improve outcomes. Is this the future of transplant medicine?